Biodexa Pharmaceuticals plc · NASDAQ:BDRX
Biodexa Pharmaceuticals — Midatech Pharma — H1 2020 Earnings Presentation
13 slides from Biodexa Pharmaceuticals's earnings presentation, Sep 10, 2020
Slide 1: Interims 2020
Interims 2020 10 September 2020
Slide 2: The Midatech senior team
The Midatech senior team LEFT TO RIGHT Fiona Sharp Group Controller Sam Barker Director Business Development Stephen Stamp CEO and CFO Paul Seaman VP Pharmaceutical & Technology Development Steve Damment EVP R&D 2
Slide 3: Disclaimer
Disclaimer The following presentation, including a hard copy of these slides/the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection with the presentation
Slide 4: YTD 2020: a period of transition for Midatech
YTD 2020: a period of transition for Midatech WHEN WHAT 2 Mar Expansion of MTX110 in DIPG with Columbia University 31 Mar Strategic Review, restructuring, cost reduction programme 20 Apr Appointment of Noble / Formal Sale Process 18 May Combined US / UK offering to raise £4.3m (gross) 8 Jun Research
Slide 5: A re-aligned strategy: collaborating and partnering early
A re-aligned strategy: collaborating and partnering early Develop in-house enhanced formulations of existing APIs in orphan/specialty Internal indications to create value Analytics / Optimization / API In vitro Partnering / Formulation manufacture In vivo Selection characterization dissolution tech
Slide 6: A diversified R&D portfolio: multiple shots on goal
A diversified R&D portfolio: multiple shots on goal ID API Therapeutic Area Administration Formulation Pre-clinical Phase I Phase II Partnering Status Q-Sphera Long acting MTD211 Small molecule CNS Injectable Long acting MTD214 Small molecule Anti-rejection Injectable Monoclonal Long acting MTD215 U
Slide 7: Q-Sphera pipeline: from 1 to 7 in four months
Q-Sphera pipeline: from 1 to 7 in four months ID API Therapeutic Area Administration Formulation Pre- clinical Phase I Phase II Partnering Status 7 programmes in all Small Q-Sphera Long acting 6 New since Strategic Review MTD211 CNS molecule Injectable MTD214 Small molecule Anti-rejection Long actin
Slide 8: MTD201 – 102: further Q-Sphera proof of concept
MTD201 – 102: further Q-Sphera proof of concept MTD201 102 : Plasma octreotide SC vs IM injection Demonstrated Q-Sphera advantages 1. Simpler reconstitution 2. Improved injectability 3. Minimal burst release 4. Predictable kinetics 5. Lower cost of goods 6. Subcutaneous administration 8
Slide 9: MTX110: clinical programme, multiple possibilities
MTX110: clinical programme, multiple possibilities 1Q20 2Q20 3Q20 4Q20 1H21 2H21 1H22 2H22 CED System DIPG Tolerability Phase I UCSF Medulloblastoma University of Phase I Exploratory Texas Columbia DIPG Exploratory Phase I University Kinderspital, Phase II DIPG Efficacy Zurich Other eg GBM N/A Pre-C
Slide 10: Summary profit & loss: 1H 2020 vs 1H 2019
Summary profit & loss: 1H 2020 vs 1H 2019 H1 2019 H1 2020 H1 2020 vs H1 2019 £m £m £m Revenue 0.45 0.17 (0.28) R&D costs 3.46 3.99 (0.53) Distribution, selling 0.19 0.01 0.18 Administrative costs 2.05 2.93 (0.88) Impairment 11.59 (11.59) Operating loss (5.24) (18.35) (13.10) Net loss (4.42) (17.42)
Slide 11: Summary profit & loss: H1 adjustments for one-time costs
Summary profit & loss: H1 adjustments for one-time costs H1 2019 H1 2020 One-time costs As adjusted £m £m £m £m Revenue 0.45 0.17 0.17 R&D costs (as stated) 3.46 3.99 Less: Redundancy costs (0.88) Spain assets write-down (0.55) Share based payment 0.35 R&D costs (as adjusted) 2.91 Distribution, sell
Slide 12: Summary liquidity: 30 June 2020 and pro forma
Summary liquidity: 30 June 2020 and pro forma At 30 June Settlement July 2020 August Pro forma 2020 Spain UK Placing 2020 liabilities warrant exercises £m £m £m £m £m Lease liabilities (0.31) 0.17 (0.14) Government loans (3.19) 3.19 - Other receivables (Reindus deposit) 2.76 (2.76) - Cash and cash e
Slide 13: Questions?
Questions? 13